Iovance Biotherapeutics clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced Melanoma

   Enrollment reduced: 100 → 24 participants

   Also in this update: Primary completion moved earlier from Dec 2032 to Dec 2027; Completion moved earlier from Dec 2033 to Jun 2028

   Iovance Biotherapeutics, Inc.·Phase 2· NCT07288203· Registry history of NCT07288203 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

2. Notable

   SARATOGA · Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced…SARATOGA · Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced Soft Tissue Sarcoma

   Recruitment opened

   Iovance Biotherapeutics, Inc.·Phase 2· NCT07741877· Registry history of NCT07741877 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.